Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Electrocardiographic features of immune checkpoint inhibitor associated myocarditis

      research-article
      1 , 2 , 2 , 2 , 2 , 3 , 4 , 5 , 6 , 7 , 2 , 1 , 1 , 8 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 2 , 2 , 15 , 16 , 5 , 17 , 18 , 19 , 20 , 21 , 17 , 17 , 22 , 23 , 24 , 25 , 24 , 8 , 1 , 2 ,
      Journal for Immunotherapy of Cancer
      BMJ Publishing Group
      autoimmunity, immune tolerance, immunotherapy, inflammation, self tolerance

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI) use that remains inadequately characterized. The QRS duration and the QTc interval are standardized electrocardiographic measures that are prolonged in other cardiac conditions; however, there are no data on their utility in ICI myocarditis.

          Methods

          From an international registry, ECG parameters were compared between 140 myocarditis cases and 179 controls across multiple time points (pre-ICI, on ICI prior to myocarditis, and at the time of myocarditis). The association between ECG values and major adverse cardiac events (MACE) was also tested.

          Results

          Both the QRS duration and QTc interval were similar between cases and controls prior to myocarditis. When compared with controls on an ICI (93±19 ms) or to baseline prior to myocarditis (97±19 ms), the QRS duration prolonged with myocarditis (110±22 ms, p<0.001 and p=0.009, respectively). In contrast, the QTc interval at the time of myocarditis (435±39 ms) was not increased compared with pre-myocarditis baseline (422±27 ms, p=0.42). A prolonged QRS duration conferred an increased risk of subsequent MACE (HR 3.28, 95% CI 1.98 to 5.62, p<0.001). After adjustment, each 10 ms increase in the QRS duration conferred a 1.3-fold increase in the odds of MACE (95% CI 1.07 to 1.61, p=0.011). Conversely, there was no association between the QTc interval and MACE among men (HR 1.33, 95% CI 0.70 to 2.53, p=0.38) or women (HR 1.48, 95% CI 0.61 to 3.58, p=0.39).

          Conclusions

          The QRS duration is increased in ICI myocarditis and is associated with increased MACE risk. Use of this widely available ECG parameter may aid in ICI myocarditis diagnosis and risk-stratification.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: not found
          • Article: not found

          Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immune checkpoint blockade: a common denominator approach to cancer therapy.

            The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study. Copyright © 2015 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

              In this position statement of the ESC Working Group on Myocardial and Pericardial Diseases an expert consensus group reviews the current knowledge on clinical presentation, diagnosis and treatment of myocarditis, and proposes new diagnostic criteria for clinically suspected myocarditis and its distinct biopsy-proven pathogenetic forms. The aims are to bridge the gap between clinical and tissue-based diagnosis, to improve management and provide a common reference point for future registries and multicentre randomised controlled trials of aetiology-driven treatment in inflammatory heart muscle disease.
                Bookmark

                Author and article information

                Journal
                J Immunother Cancer
                J Immunother Cancer
                jitc
                jitc
                Journal for Immunotherapy of Cancer
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2051-1426
                2021
                2 March 2021
                : 9
                : 3
                : e002007
                Affiliations
                [1 ]departmentCardio-Oncology Program, Division of Cardiology, Department of Medicine , Massachusetts General Hospital , Boston, Massachusetts, USA
                [2 ]departmentCardiovascular Imaging Research Center (CIRC), Division of Cardiology and Department of Radiology , Massachusetts General Hospital , Boston, Massachusetts, USA
                [3 ]departmentCardio-Oncology Program, Cardiology Division, NewYork-Presbyterian Hospital , Weill Cornell Medicine , New York, New York, USA
                [4 ]departmentCardio-Oncology Program, Division of Cardiology, Department of Medicine , Montefiore Medical Center, Albert Einstein College of Medicine , Bronx, New York, USA
                [5 ]departmentCardiology Division , Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine , New York, New York, USA
                [6 ]departmentCardio-Oncology Program, Division of Cardiology , Hopitaux Universitaires Est Parisien , Paris, France
                [7 ]departmentCardio-Oncology Program , MedStar Heart and Vascular Institute, MedStar Washington Hospital Center , Washington, DC, USA
                [8 ]departmentCardio-Oncology Program, Division of Cardiovascular Medicine , H. Lee Moffitt Cancer Center & Research Institute and University of South Florida , Tampa, Florida, USA
                [9 ]departmentDepartment of Dermatology , University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) , Erlangen, Germany
                [10 ]departmentDiscipline of Cardiology, Department of Medicine , Faculty of Medical Science, State University of Campinas , Campinas, Brazil
                [11 ]departmentDivision of Oncology and Hematology, Department of Medicine , Lehigh Valley Hospital , Allentown, Pennsylvania, USA
                [12 ]departmentCardiology Division , Mount Sinai Medical Center , New York, New York, USA
                [13 ]departmentCardio-Oncology Program, Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University School of Medicine , Atlanta, Georgia, USA
                [14 ]departmentDepartment of Translational Medical Sciences, Interdepartmental Center of Clinical and Translational Research (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA) , Università degli Studi di Napoli Federico II , Naples, Italy
                [15 ]departmentCardiology Department , Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red CardioVascular (CIBER-CV) , Madrid, Spain
                [16 ]departmentFaculty of Medicine , University of Southampton , Southampton, UK
                [17 ]departmentMassachusetts General Hospital Cancer Center, Department of Medicine , Massachusetts General Hospital , Boston, Massachusetts, USA
                [18 ]departmentCardio-Oncology Program, Division of Cardiovascular Medicine , Lahey Hospital and Medical Center , Burlington, Massachusetts, USA
                [19 ]departmentUCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine , University of California at Los Angeles , Los Angeles, California, USA
                [20 ]departmentDepartment of Dermatology and Allergy , LMU Klinikum , Munich, Germany
                [21 ]departmentMediterranean University Center of Cardio-Oncology , Aix-Marseille University, North Hospital , Marseille, France
                [22 ]departmentAbramson Cancer Center , Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania, USA
                [23 ]departmentCardio-Oncology Service , Royal Brompton Hospital and Imperial College London , London, UK
                [24 ]departmentCardio-Oncology Program, Division of Cardiology, Department of Medicine , Brigham and Women's Hospital , Boston, Massachusetts, USA
                [25 ]departmentTed Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Division of Cardiology , Toronto General Hospital, University of Toronto , Toronto, Ontario, Canada
                Author notes
                [Correspondence to ] Tomas G Neilan; tneilan@ 123456mgh.harvard.edu
                Author information
                http://orcid.org/0000-0001-9007-7295
                http://orcid.org/0000-0002-8727-7154
                Article
                jitc-2020-002007
                10.1136/jitc-2020-002007
                7929895
                33653803
                36518dcf-4657-41e6-bfc7-5d32799365fa
                © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 24 January 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000050, National Heart, Lung, and Blood Institute;
                Award ID: K24HL150238
                Award ID: R01HL130539
                Award ID: R01HL137562
                Award ID: T32HL007208-39
                Funded by: National Cancer Institute;
                Award ID: P30CA008748
                Categories
                Clinical/Translational Cancer Immunotherapy
                1506
                2435
                Original research
                Custom metadata
                unlocked

                autoimmunity,immune tolerance,immunotherapy,inflammation,self tolerance

                Comments

                Comment on this article